For instance, Chi et al. have reported that C1QTNF6 improves PPARγ activation to alleviate angiotensin II-induced hypertension and vascular endothelial dysfunction in spontaneously hypertensive rats; Murayama et al. demonstrated that C1QTNF6 is an endogenous complement regulator that can effectively treat induced arthritis; and in 2019, Han et al. revealed that C1QTNF6 as a novel biomarker regulates cellular behaviors in A549 cells and exacerbates the outcome of lung adenocarcinoma patients. Here, PPARG is linked to lung adenocarcinoma.